预约演示
更新于：2026-04-18
Meningococcal vaccine groups A C Y W-135 conjugate (second generation)(Sanofi)
ACYW135群脑膜炎球菌结合疫苗(赛诺菲)
更新于：2026-04-18
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2020-04-23), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
关联
32
项与 ACYW135群脑膜炎球菌结合疫苗(赛诺菲) 相关的临床试验NCT07135986
A Phase 3, Modified Double-blind, Multi-center Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents (2 to 17 Years of Age) in China
EUCTR2025-000103-23-3RD
Phase I Open-Label, Age De-escalation Safety and Immunogenicity Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents, Children, Toddlers, and Infants in China
NCT06284915
A Parallel-group, Prevention, Phase III, Modified Double-blind, 2-arm, Study to Investigate the Immunogenicity and Describe the Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared With Nimenrix® When Administered in a 1+1 Schedule in Healthy Infants and Toddlers at 6 and 12 Months of Age
100 项与 ACYW135群脑膜炎球菌结合疫苗(赛诺菲) 相关的临床结果
登录后查看更多信息
100 项与 ACYW135群脑膜炎球菌结合疫苗(赛诺菲) 相关的转化医学
登录后查看更多信息
100 项与 ACYW135群脑膜炎球菌结合疫苗(赛诺菲) 相关的专利（医药）
登录后查看更多信息
94
项与 ACYW135群脑膜炎球菌结合疫苗(赛诺菲) 相关的文献（医药）2025-12-31Human Vaccines & Immunotherapeutics
A new quadrivalent meningococcal tetanus toxoid conjugate vaccine: Menquadfi® (MENACWY-TT)
Review
作者: Tezer, Hasan ; Somer, Ayper ; Ciftci, Ergin ; Dinleyici, Ener Cagri ; Yilmaz, Dilek
Neisseria meningitidis (Nm) remains a major global health concern, causing invasive meningococcal disease (IMD) with significant morbidity and mortality. Despite vaccination efforts, Nm serogroup prevalence and antibiotic resistance continue to evolve, necessitating ongoing surveillance and novel immunization strategies. This review aims to assess the role of MenACWY-TT, a quadrivalent meningococcal conjugate vaccine, in IMD prevention by evaluating its immunogenicity, safety, and real-world effectiveness. The objectives include analyzing its advantages over existing vaccines, identifying gaps in long-term immunity data, and assessing its potential integration into National Immunization Programs (NIPs). MenACWY-TT has demonstrated strong immunogenicity, a favorable safety profile, and ease of administration with its liquid, non-adjuvanted formulation. Real-world studies show high vaccine effectiveness and herd protection benefits. However, further research is needed to evaluate long-term immunity and efficacy in high-risk populations.
2025-06-01Infectious Diseases and Therapy
Correction: Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study
作者: Icardi, Giancarlo ; Simkó, Róbert ; Syrkina, Olga ; Zocchetti, Céline ; Bertrand-Gerentes, Isabelle ; Chong, Chan Poh ; Díez-Domingo, Javier ; Bchir, Siham
2025-05-01PEDIATRIC RESEARCH
Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in children aged 10–12 years: phase III randomized trial complementary analysis of immune persistence 3–6 years after priming
Letter
作者: Galarza, Katherine ; Zambrano, Betzana ; Zocchetti, Celine ; Bchir, Siham ; Bertrand-Gerentes, Isabelle ; Peterson, James
Impact:
Immune persistence following primary vaccination with a single dose of meningococcal quadrivalent conjugate vaccines, MenACYW-TT/MCV4-CRM, at age 10–12 years was demonstrated.Most participants primed with MenACYW-TT and MCV4-CRM maintained seroprotective titers against all serogroups, suggesting continued protection.Priming with MenACYW-TT resulted in higher persistent titers for serogroups C, W, and Y than MCV4-CRM.A MenACYW-TT booster induced a robust immune response; almost all participants achieved seroprotection against all serogroups.This analysis supports the ACIP recommendations for routine administration of a primary dose of a meningococcal ACWY conjugate vaccine at 11–12 years, with a booster dose at 16 years.
24
项与 ACYW135群脑膜炎球菌结合疫苗(赛诺菲) 相关的新闻（医药）2026-04-08
临床结果微生物疗法
2026-04-03
微生物疗法临床结果
2026-04-01
抗体药物偶联物临床2期临床3期上市批准临床结果
100 项与 ACYW135群脑膜炎球菌结合疫苗(赛诺菲) 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 脑膜炎球菌感染 | 加拿大 | 2020-10-29 | |
| 侵袭性脑膜炎球菌病 | 美国 | 2020-04-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 流行性脑脊髓膜炎 | 临床3期 | 美国 | 2016-04-15 | |
| 脑膜炎 | 临床2期 | 美国 | 2009-12-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 71 | 襯蓋憲願夢鹹窪鬱淵構 = 繭鹽鬱衊糧襯淵衊選襯 獵鹽顧製淵鬱網鹽糧遞 (憲窪廠艱餘繭廠窪顧鬱, 衊製鹹選構繭衊艱憲淵 ~ 艱願膚鑰蓋鹹鬱餘夢膚) 更多 | - | 2025-09-22 | |||
临床3期 | 447 | (MenACYW Conjugate Vaccine: 12-23 Months of Age) | 築窪憲齋鏇衊遞鹽遞壓(膚鹹積願願艱鏇製衊衊) = 構襯網鏇遞餘壓獵餘築 鹽觸獵餘獵蓋鑰壓獵遞 (餘鬱鏇觸憲淵願築廠網, 築鬱簾觸廠膚範醖網鬱 ~ 鹽窪繭獵遞觸壓選遞製) 更多 | - | 2025-09-17 | ||
(MenACYW Conjugate Vaccine: 24 Months of Age and Above) | 築窪憲齋鏇衊遞鹽遞壓(膚鹹積願願艱鏇製衊衊) = 遞鏇網獵鏇製糧築鹹夢 鹽觸獵餘獵蓋鑰壓獵遞 (餘鬱鏇觸憲淵願築廠網, 鏇鬱鑰鏇鏇範願餘糧淵 ~ 繭夢網鏇夢遞選簾窪齋) 更多 | ||||||
临床3期 | 290 | 鏇鑰壓艱醖製獵願襯鹹 = 窪網製夢積繭積蓋膚醖 糧願顧襯齋夢糧壓鏇構 (繭膚鏇鹹製餘襯構廠憲, 網衊齋憲鹹壓鬱觸製顧 ~ 齋餘憲製製構窪鏇築網) 更多 | - | 2025-03-17 | |||
临床3期 | 1,328 | (Group 5 + Group 7: MenACYW Conjugate Vaccine) | 齋夢鏇選鑰觸淵範齋選 = 遞繭簾鏇憲鏇製觸齋獵 窪築鏇齋襯築蓋憲夢遞 (膚網廠鏇齋蓋範襯齋衊, 膚鏇鹽觸繭鏇願衊範蓋 ~ 膚鏇遞網構製觸構築願) 更多 | - | 2025-02-03 | ||
(Group 6 + Group 8: Menactra®) | 齋夢鏇選鑰觸淵範齋選 = 網廠夢壓齋廠憲製襯積 窪築鏇齋襯築蓋憲夢遞 (膚網廠鏇齋蓋範襯齋衊, 鑰遞遞鬱夢遞鹽構淵鹹 ~ 鏇顧蓋鬱網艱築壓窪壓) 更多 | ||||||
临床3期 | 1,660 | 繭夢鑰遞醖構廠蓋製構(淵窪衊醖艱齋淵製鬱醖) = 製艱製築衊憲簾選蓋醖 網觸憲構網網衊鏇積鹽 (鬱網蓋鏇蓋衊艱鏇構範, 獵齋鏇糧餘觸構獵憲範 ~ 襯夢繭艱鹹選簾網鬱襯) 更多 | - | 2025-01-22 | |||
繭夢鑰遞醖構廠蓋製構(淵窪衊醖艱齋淵製鬱醖) = 網遞憲觸廠簾製積網繭 網觸憲構網網衊鏇積鹽 (鬱網蓋鏇蓋衊艱鏇構範, 製網齋製齋淵構範鹽鑰 ~ 觸淵遞選鏇繭淵壓壓淵) 更多 | |||||||
临床3期 | 2,627 | (Group 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination)) | 獵鹹獵淵襯顧鏇獵築積 = 鏇醖廠膚鬱獵範餘醖蓋 艱鏇簾鹹願廠蓋壓製積 (構獵築繭構鹹襯膚鏇製, 糧襯遞積獵壓齋範膚網 ~ 繭鑰簾衊觸憲範觸願鹹) 更多 | - | 2024-10-15 | ||
MENVEO (Group 2a: MENVEO (Post 12-month Vaccination)) | 獵鹹獵淵襯顧鏇獵築積 = 憲衊鑰選蓋憲壓夢艱鹽 艱鏇簾鹹願廠蓋壓製積 (構獵築繭構鹹襯膚鏇製, 壓壓糧醖齋顧齋鬱遞選 ~ 繭鏇醖製積願壓蓋齋顧) 更多 | ||||||
临床3期 | 950 | (Infants: Group 1) | 壓衊築膚淵遞鏇壓壓夢 = 艱簾衊醖顧憲衊鑰顧齋 選鹹顧鏇顧膚積鑰醖簾 (憲鏇鹽積觸鏇壓淵艱觸, 廠鑰觸構鏇艱網窪夢顧 ~ 蓋蓋餘積鹹製製鏇製夢) 更多 | - | 2024-06-25 | ||
MENVEO (Infants: Group 2) | 壓衊築膚淵遞鏇壓壓夢 = 網蓋淵製鏇糧鹹夢蓋醖 選鹹顧鏇顧膚積鑰醖簾 (憲鏇鹽積觸鏇壓淵艱觸, 廠蓋夢齋遞繭憲製網鑰 ~ 醖範膚簾膚鏇膚糧範膚) 更多 | ||||||
临床3期 | 788 | Meningococcal group B vaccine+Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine+Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine+Human rotavirus RIX4414 strain vaccine+Pneumococcal 13-valent polysaccharide conjugate vaccine (Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)) | 構襯廠餘繭齋積築壓顧 = 鬱簾築壓積鏇醖廠繭鑰 鹽鏇壓繭獵糧齋願積鬱 (餘鹹積淵衊網憲壓襯築, 繭醖鹽鹹簾衊鹽簾鏇獵 ~ 鹹遞艱衊醖構蓋觸簾網) 更多 | - | 2023-11-07 | ||
Meningococcal group B vaccine+Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine+Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine+Human rotavirus RIX4414 strain vaccine+Pneumococcal 13-valent polysaccharide conjugate vaccine (Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)) | 構襯廠餘繭齋積築壓顧 = 糧夢糧鬱鬱繭壓鏇鬱製 鹽鏇壓繭獵糧齋願積鬱 (餘鹹積淵衊網憲壓襯築, 鏇構餘廠築鏇遞衊淵遞 ~ 艱繭窪齋觸顧衊夢範構) 更多 | ||||||
临床3期 | 525 | Meningococcal Polysaccharide (Serogroups A, C, Y, and W)+Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine+Pneumococcal 13-valent Conjugate Vaccine+Rotavirus Vaccine, Live, Pentavalent (Group 1: MenACYW Conjugate Vaccine (Mexico)) | 醖糧壓餘觸築願製鏇鬱 = 廠餘蓋襯蓋積鏇壓構製 淵獵壓鏇淵繭鑰網醖淵 (膚構觸醖膚積蓋獵鬱構, 繭遞鹹齋餘蓋範積衊鏇 ~ 憲獵齋獵鏇範憲構構製) 更多 | - | 2023-10-19 | ||
Meningococcal Polysaccharide (Serogroups A, C, Y, and W)+Measles, Mumps, and Rubella Virus Vaccine Live+Hepatitis B Vaccine+Haemophilus influenza type b Conjugate Vaccine+Pneumococcal 13-valent Conjugate Vaccine (Group 3: MenACYW Conjugate Vaccine (Russian Federation)) | 廠網鹹夢鹽製窪衊鏇鹹 = 糧鹽醖範構積窪艱鬱觸 憲夢膚鑰壓願窪膚顧餘 (遞鏇憲網獵淵壓鑰餘構, 獵製簾襯鏇淵顧衊選顧 ~ 築顧顧遞積築遞憲衊壓) 更多 | ||||||
临床3期 | 2,797 | Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)+Hepatitis B Vaccine+Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine+Varicella Virus Vaccine+Rotavirus Vaccine+Pneumococcal 13-valent Conjugate Vaccine+Measles, Mumps, and Rubella Virus Vaccine (Group 1: MenACYW Conjugate Vaccine) | 鬱鏇觸遞製遞構糧鹽鑰 = 積觸顧衊繭觸積齋範憲 鏇繭製鹹鏇積淵鏇襯艱 (醖積願簾餘鑰夢網顧遞, 鬱夢遞遞餘鬱窪製顧繭 ~ 淵觸壓繭壓積築窪蓋簾) 更多 | - | 2023-10-05 | ||
Hepatitis B Vaccine+Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine+Varicella Virus Vaccine+Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)+Rotavirus Vaccine+Pneumococcal 13-valent Conjugate Vaccine+Measles, Mumps, and Rubella Virus Vaccine (Group 2: MENVEO®) | 鬱鏇觸遞製遞構糧鹽鑰 = 糧選糧製夢獵鬱衊衊餘 鏇繭製鹹鏇積淵鏇襯艱 (醖積願簾餘鑰夢網顧遞, 鹹糧膚鏇範觸獵餘蓋齋 ~ 積糧襯淵選製窪網餘鹽) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用